丘脑弥漫中线胶质瘤H3 K27变异型与丘脑胶质母细胞瘤的临床与生存差异
本研究回顾性比较丘脑DMG-H3 K27-altered与丘脑GBM的临床特征和生存。按Stupp方案治疗时,DMG-H3 K27-altered中位OS显著长于GBM(26.3 vs 14.7个月,p=0.019)。在DMG-H3 K27-altered中,MRI轻度或无强化与OS延长显著相关(26.3 vs 13.7个月,p=0.031)。
要点
- 丘脑DMG-H3 K27-altered患者较GBM更年轻,Ki67指数更低,MGMT启动子甲基化率更低。
- 按Stupp方案治疗时,丘脑DMG-H3 K27-altered的中位OS显著优于GBM。
- 丘脑DMG-H3 K27-altered中,MRI轻度或无强化与更长的OS显著相关。
核心结论
- 按Stupp方案治疗时,丘脑DMG-H3 K27-altered的OS优于丘脑GBM。
- 丘脑DMG-H3 K27-altered中,MRI轻度或无强化与OS延长显著相关。
研究设计与样本
- 回顾性单中心研究,纳入44例丘脑GBM和43例丘脑DMG-H3 K27-altered患者。
- 总结临床特征、病理、治疗方式及预后,采用Kaplan-Meier和Cox回归进行生存分析。
主要发现
- DMG-H3 K27-altered组较GBM组显著年轻(中位年龄40 vs 49岁,p=0.039)。
- DMG-H3 K27-altered组Ki67指数更低,MGMT启动子甲基化率更低。
- 按Stupp方案治疗时,DMG-H3 K27-altered中位OS显著长于GBM(26.3 vs 14.7个月,p=0.019)。
- DMG-H3 K27-altered中,MRI轻度或无强化者OS显著更长(26.3 vs 13.7个月,p=0.031)。
临床怎么用
- 丘脑中线病变应鉴别DMG-H3 K27-altered与GBM,并参考分子病理结果。
- 按Stupp方案治疗时,DMG-H3 K27-altered的生存预期可能优于GBM。
- MRI强化程度可能有助于丘脑DMG-H3 K27-altered的预后判断。
局限性
- 回顾性单中心研究,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The 2021 WHO classification describes a specific subgroup of diffuse midline glioma, H3 K27-altered (DMG-H3 K27-altered), which arises in the thalamus or other midline structures. To date, the prognosis of thalamic DMG-H3 K27-altered remains controversial, and no studies have compared its overall survival (OS) with that of glioblastoma (GBM). The present study aimed to compare the clinical features and survival outcomes of patients with thalamic DMG-H3 K27-altered and those with thalamic GBM. METHODS: This was a retrospective, single-center study. The clinical characteristics, pathological findings, treatment modalities, and prognostic outcomes of the patients were summarized. Survival analyses were conducted using the Kaplan-Meier and Cox regression analyses. RESULTS: We screened 44 patients diagnosed with thalamic GBM, and 43 with thalamic DMG-H3 K27-altered. Compared with GBM, patients with DMG-H3 K27-altered were significantly younger (median age: 40 vs. 49 years, p = 0.039), exhibited lower Ki67 index, and had less MGMT promoter methylation rates. The median OS was significantly prolonged in thalamic DMG-H3 K27-altered compared with GBM among patients treated according to the Stupp protocol (26.3 vs. 14.7 months, p = 0.019). In patients with thalamic DMG-H3 K27-altered group, slight or no enhancement on magnetic resonance imaging (MRI) was significantly associated with prolonged OS (26.3 vs. 13.7 months, p = 0.031). CONCLUSIONS: The OS of thalamic DMG-H3 K27-altered was superior to GBM among patients who received treatment according to the Stupp-protocol. Slight or no enhancement on MRI was significantly associated with prolonged OS in patients with thalamic DMG-H3 K27-altered.
引用
- Ji P, Li C, Wang Y, et al. Clinical and survival differences between thalamic glioblastoma and thalamic diffuse midline glioma, H3 K27-altered. J Neurooncol. 2025. PMID: 41144061. doi:10.1007/s11060-025-05273-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。